- Home
- LIXT vs YOOV Comparison
LIXT vs YOOV Comparison
Compare LIXT & YOOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$7.15
N/A
Current Price
$0.41
Company Overview
Basic Information| Metric | LIXT | YOOV |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | Singapore |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 126.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | LIXT | YOOV |
|---|---|---|
| Price | $7.15 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 369.7K | 34.0K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.41 |
| 52 Week High | $7.78 | $0.51 |
Technical Indicators
Market Signals| Indicator | LIXT | YOOV |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | N/A |
| Support Level | $3.82 | N/A |
| Resistance Level | $7.64 | N/A |
| Average True Range (ATR) | 0.72 | 0.00 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 66.40 | 0.00 |
Price Performance
Historical Comparison LIXT
YOOV
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.